A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors

NCT06041516 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

70

Enrollment

NIH

Sponsor class

Conditions

Neuroendocrine Carcinomas
Neuroendocrine Tumors
Carcinoma, Neuroendocrine
Carcinoma, Adrenocortical
Carcinoma, Adrenal Cortical

Interventions

DRUG: ADCT-701

Sponsor

National Cancer Institute (NCI)